Login
  • Therapeutic Area
    • Metabolic
    • Cardiovascular
      SPAF RWE Data Visualization Tool
    • Oncology
    • Respiratory
    • Inflammation
    • Heart Failure
  • Products
    All products
    • Metabolic
      EmpagliflozinLinagliptinEmpagliflozin + Linagliptin
    • Cardiovascular
      Dabigatran etexilateTelmisartan
    • Oncology
      Afatinib
    • Respiratory
      Tiotropium + olodaterolCombivent
    • Inflammation
      Nintedanib
    • Heart Failure
      Empagliflozin
  • Elearning
  • PODCASTS
  • Contact
Login

  • Add
  • YOUR FORESIGHT. HIS FUTURE.
    The first NOAC with
    a reversal agent

    YOUR FORESIGHT.
    HIS FUTURE.

    Dabigatran etexilate (Pradaxa®) is proven to be safe and effective to lower the risk of stroke and gives you the assurance of reversibility with Idarucizumab (Praxbind®) in emergency situations.
     
    Close ×
    • Therapeutic Area
    • Metabolic
    • Cardiovascular
    • Oncology
    • Respiratory
    • Inflammation
    • Heart Failure
    • eLearning
    • Resources
    • Videos
    • Clinical studies
    • Site map
    • Terms of use
    • Privacy
    • Contact
    • Change country

    Copyright © 2026 Boehringer Ingelheim (Philippines), Inc. All rights reserved. Use of this Site is subject to the Terms of Use and Privacy Statement.

    This website is intended for healthcare professionals in the Philippines. The contents of this website are for information purposes only and are not intended to substitute for advice, treatment or recommendations of a healthcare professional. For your health concerns and other questions about symptoms, treatment or medication, consult a healthcare professional.